Biomea Fusion Prices Public Offering at $25M for Diabetes, Obesity Drugs
Biomea Fusion, Inc. (Nasdaq: BMEA) has priced its public offering at approximately $25.0 million. The offering, led by Jefferies as sole book-running manager and H.C. Wainwright & Co. as lead manager, includes a mix of common stock, pre-funded warrants, and accompanying warrants. It is expected to close on October 8, 2025, subject to customary closing conditions.
Biomea Fusion, a clinical-stage company focused on diabetes and obesity medicines, is offering 11,195,121 shares of common stock and accompanying warrants, along with up to 1,000,000 pre-funded warrants with accompanying warrants. The underwriters have a 30-day option to purchase up to an additional 1,829,268 shares and/or warrants. The offering is being conducted pursuant to an effective shelf registration statement on Form S-3 with the SEC. Interested investors can obtain copies of the final prospectus supplement and accompanying prospectus from Jefferies LLC or the SEC's website. The offering is subject to market conditions and may not be completed on the anticipated terms or at all. Biomea's forward-looking statements are subject to risks and uncertainties, as detailed in its filings with the SEC.
Biomea Fusion's public offering, priced at approximately $25.0 million, is set to close on October 8, 2025. The offering, managed by Jefferies and H.C. Wainwright & Co., aims to raise funds for the company's clinical-stage diabetes and obesity medicines. Investors should review the final prospectus supplement and accompanying prospectus for detailed information.
